标题
Tumor clone dynamics in lethal prostate cancer
作者
关键词
-
出版物
Science Translational Medicine
Volume 6, Issue 254, Pages 254ra125-254ra125
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2014-09-18
DOI
10.1126/scitranslmed.3009448
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Recurrent Prostate Cancer Genomic Alterations Predict Response to Brachytherapy Treatment
- (2014) J. Fontugne et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Punctuated Evolution of Prostate Cancer Genomes
- (2013) Sylvan C. Baca et al. CELL
- Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
- (2013) D. Bianchini et al. EUROPEAN JOURNAL OF CANCER
- Tracking the clonal origin of lethal prostate cancer
- (2013) Michael C. Haffner et al. JOURNAL OF CLINICAL INVESTIGATION
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
- (2012) Alison H M Reid et al. MODERN PATHOLOGY
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
- (2012) Christopher E Barbieri et al. NATURE GENETICS
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
- (2012) T. Forshew et al. Science Translational Medicine
- Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing
- (2012) R. J. Leary et al. Science Translational Medicine
- Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
- (2009) Gerhardt Attard et al. CANCER CELL
- Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
- (2009) G. Attard et al. CANCER RESEARCH
- Distinct genomic aberrations associated withERGrearranged prostate cancer
- (2009) Francesca Demichelis et al. GENES CHROMOSOMES & CANCER
- Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
- (2009) Wennuan Liu et al. NATURE MEDICINE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started